Navigation Links
Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations regarding its novel histone deacetylase (HDAC) inhibitor and Bruton's tyrosine kinase inhibitor compounds. The presentations will take place at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held April 14-18, 2007, at the Los Angeles Convention Center, in Los Angeles, CA.

    The presentations are as follows:


    Sunday, April 15, 2007

    Session: HDAC Inhibitors 1

    Poster Presentation: Mechanisms of sensitivity in primary hematopoietic

    tumors and tumor lines to a novel HDAC inhibitor PCI-24781

    Abstract #678:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: HDAC Inhibitors 1

    Poster Presentation: Radiosensitization by the HDAC inhibitor PCI-24781 in

    SiHa and WiDr human tumor cell lines

    Abstract #695:  8:00 a.m. -12:00 p.m.

    Presenter:  Peggy L. Olive, Ph.D., British Columbia Cancer Research Center


    Monday, April 16, 2007

    Session: Targeted Agents and Other Novel Therapies

    Poster Presentation: Identification of cross-validated functional

    biomarkers for a novel HDAC inhibitor PCI-24781, and their utility for

    selection of clinical indications

    Abstract #1830:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: DNA Repair and Chemotherapeutic Agent Resistance

    Poster Presentation: Novel histone deacetylase (HDAC) inhibitor PCI-24781

    disrupts RAD51 foci and inhibits homologous recombination

    Abstract #1966:  8:00 a.m. -12:00 p.m.

    Presenter:  Shanthi Adimoolam, Ph.D., Pharmacyclics, Inc.


    Wednesday, April 18, 2007

    Session: Kinases 1

    Poster Presentation: PCI-31523: An irreversible inhibitor of Bruton's

    tyrosine kinase (Btk) that disrupts B cell receptor (BCR) signaling, is

    cytotoxic to B cell lympho
mas, and is active in an animal arthritis model

    Abstract #5398:  8:00 a.m. -12:00 p.m.

    Presenter:  Lee Honigberg, Ph.D., Pharmacyclics, Inc.


    Session: Miscellaneous Anticancer Agents

    Poster Presentation: Synthesis and anticancer properties of water-soluble

    zinc ionophores

    Abstract #5606:  8:00 a.m. -12:00 p.m.

    Presenter:  Darren Magda, Ph.D., Pharmacyclics, Inc.

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, and products can be found at www.pharmacyclics.com . Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forwar d-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the possibility that the FDA declines to schedule an advisory panel meeting to review our NDA; the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the preparation of our NDA filing and the product development of our pipeline; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065, for Pharmacyclics,Inc.

Web site: http://www.pharmacyclics.com/

Ticker Symbol: (NASDAQ-NMS:PCYC)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017   ... to protecting the rights of victims injured by ... prompted regulators to call for better reporting. Congress ... Safety concerns involving power morcellators and ... (FDA) to investigate how hospitals report injuries and ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: PRGO) today ... and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral ... Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 ... relief of cough in adults and children 6 years of ... January 2017 were approximately $16 million.   ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... Austin, Tx (PRWEB) , ... February 17, 2017 ... ... of revenue cycle management services, announced today that Karen Pilley has been promoted ... expenses is critical in today’s shifting healthcare paradigm – a shift that demands ...
Breaking Medicine News(10 mins):